Guanosine Analogue for the Treatment of SARS-CoV-2

Deeper understanding of coronaviruses life cycles has resulted in the discovery and validation of several targets for therapeutic intervention, and an increase in the categories of antiviral drugs. Armed with multidisciplinary drug discovery expertise and unparalleled scope of capabilities in platforms, Creative Biolabs is competent to deliver depth and breadth in science with data and insight to progress your guanosine analogue drug discovery for SARS-CoV-2.

Guanosine Analogue and Coronaviruses

Recently, some new guanosine analogues have been developed, such as the 3-membered (cyclopropyl) sugar derivative A-5021, the 6-membered D- and L-cyclohexenyl derivatives. Prominent features shared by all guanosine analogues:

• They depend on their phosphorylation on the virus-encoded thymidine kinase (TK).
• They are active against HCMV, whether or not they are subject of phosphorylation by the HCMV-induced UL97 protein kinase.
• Their antiviral activity can be markedly potentiated by mycophenolic acid.

Several guanosine analogues, such as acyclovir, penciclovir and ganciclovir, are widely used for the treatment of herpesvirus infections. Besides, the acyclic guanosine analogs R- and S-enantiomers of 9-(3,4-dihydroxybutyl)guanine [(R)- and (S)-DHBG], 9-(4-hydroxybutyl)guanine (HBG), and 9-(2-hydroxyethoxymethyl)guanine (ACV) are examined for their effects on human cytomegalovirus (CMV) replication. Ribavirin is a guanosine analogue with broad-spectrum antiviral activity and it has been used in the treatment of coronaviruses infection, HCV infection, severe respiratory syncytial virus infection, viral haemorrhagic fevers. Its exact mechanism of the action is undetermined, but inhibition of mRNA capping and induction of mutations in RNA-dependent viral replication are considered to be important for coronaviruses.

Why Creative Biolabs?

Creative Biolabs has spent years on developing different series of flexible guanosine analogue. Once a candidate is identified as "active" through the first-round screening, more deep characterization of the compound will be offered for studying the effect, biophysical characters and cellular activities.

• Comprehensive and advanced CreDA™ developability assessment service for our guanosine analogue candidates, in order to address the issues that may lead to potential clinical failure.
• Biophysical Characterization and Modeling of Guanosine Analogue Inhibitors
• Molecular Engineering
• In Vitro Pharmacodynamics

At Creative Biolabs, our featured discovery solutions eliminate challenges and generate better drug candidates faster. Our team will work with you to design experiments and get the results you need to make critical decisions and advance your projects. No one else offers the same collaborative approach or generates high-quality data faster. If you are interested in our guanosine analogue inhibitors development services for SARS-CoV-2, please feel free to contact us for more information.

For Research Use Only. We do not provide direct services or products for patients.